Please select the eligibility criteria that correspond to the clinical trial below.
Title: LabAlert: Enhancing Medication Safety Through Electronic Interventions to Improve Medication Safety
Brief Summary: Errors and preventable adverse events associated with medication prescription and dispensing are common, and the difference between guideline recommendations and the actual frequency of laboratory monitoring is substantial. This study evaluates three interventions to improve laboratory monitoring at initiation of medication therapy: an electronic medical record reminder to the prescribing clinician (EMR), an automated voice message to the patient (AVM), and a pharmacy team outreach (Pharmacy) compared to usual care (UC).


Options:
A: Inclusion Criteria:

* Males or females, age 21-85
* Taking 0-3 antihypertensive medications with no changes in regimen or dose within the past 4 weeks
* Non-diabetic with clinic BP 145-179 / 95-109 or diabetic with BP greater than 135/85

Exclusion Criteria:

* Previous 24 hour BP monitoring consult service within the past 6 months
* Stage 3 hypertension greater than 180/110
* Recent MI or stroke within the past 6 months
* Class III or IV congestive heart failure
* Unstable angina
* Uncontrolled atrial fibrillation
* Serious renal disease (serum creatinine greater than 3.5)
* Serious hepatic disease (total bilirubin greater than 3.0)
* Pregnancy
* Poor prognosis with less than a 3 year life expectancy
B: Inclusion Criteria for Phase II:

* Poorly controlled blood pressure based on clinic blood pressures
* Males or females, over 21 years of age
* Taking zero to three BP medications with no change in the regimen or dose within the past 4 weeks
* Have established medical care at the Family Medicine Clinic
* Nondiabetic patients with clinic BP values (average of the last three clinic readings during the previous 12 months) of 140 to 179 mm Hg systolic BP or 90 to 109 mm Hg diastolic BP, or diabetic patients with clinic BP values of 130 to 179 systolic or 80 to 109 diastolic

Exclusion Criteria for Phase II:

* Stage 3 hypertension (BPs greater than 180/110 mm Hg), or any evidence of hypertensive urgency or emergency
* Recent myocardial infarction or stroke (within the past 6 months prior to enrollment)
* New York Heart Association Class III or IV congestive heart failure
* Unstable angina
* Serious renal or hepatic disease, including greater than or equal to 1 gram of proteinuria per day
* Pregnancy
* Poor prognosis with a life expectancy estimated at less than 3 years
* Dementia or cognitive impairment
C: Inclusion Criteria:

* age 50 and older
* prescription for at least one cardiovascular medication for heart failure
* plan to receive care and prescriptions at the study health care facility
* ability to hear within the normal range of conversation
* English speaking
* willingness to obtain echocardiography

Exclusion Criteria:

* dementia
D: Inclusion Criteria:

* Dispensed one of 12 drugs or classes of drugs where baseline safety laboratory monitoring is recommended and labs have not been completed 6 months prior or 5 days after the dispense of the medication.
* 18 years of age or older
* 12-month HMO membership
* drug benefit coverage
* has telephone number

Exclusion Criteria:

* recommended baseline laboratory monitoring completed
* receives care and/or resides in hospice, nursing home, care outside HMO
* enrolled in other care management program
* nonEnglish speaking needing translation services

Answer: D